Drug Pricing Hospitals Packaging 
STAT
SEPTEMBER 7, 2023
The ins and outs of the new House health package House Republicans on three panels circulated a draft health price transparency package with some reforms to payment practices of PBMs and hospitals, I reported yesterday. Sign up here to receive this newsletter in your inbox on Tuesdays and Thursdays.
STAT
FEBRUARY 26, 2024
WASHINGTON — Congress will not move forward with a controversial policy to equalize certain Medicare payments to hospitals and physicians’ offices in an upcoming government funding package, five lobbyists and sources following the talks told STAT.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
OCTOBER 27, 2023
8 on legislation that includes substance abuse and mental health policies, reforms to drug middlemen’s business practices, and extensions to provider payment policies in Medicare and Medicaid, according to five health care lobbyists. WASHINGTON — The Senate Finance Committee plans to vote Nov. Read the rest…
STAT
NOVEMBER 8, 2023
WASHINGTON — A prominent Senate panel on Wednesday passed a new package of health policy reforms that would rein in certain pharmacy middlemen practices and ensure Medicare patients aren’t paying more than insurers do for medications. The package passed the committee 26-0 with no amendments added. Ron Johnson (R-Wis.)
STAT
SEPTEMBER 19, 2023
About last night… House leadership last night canceled a scheduled vote on a health care package that included transparency requirements for hospitals and insurers, reforms to some PBM practices, and a small site-neutral payment policy for administering drugs, Rachel writes.
STAT
JULY 24, 2023
The House Ways & Means Committee package includes a new provision that would ensure that patients in the Medicare program pay for medicines they pick up at the pharmacy counter based on the discounted price that insurers negotiate with drugmakers, instead of higher sticker prices, starting in 2027.
STAT
JULY 25, 2023
The company had said in April it would pause or discontinue at least four studies of experimental drugs to focus on more lucrative options including the Leqembi launch and trim costs. The bill includes a separate version of price transparency legislation for hospitals, pharmacy benefit managers, and insurers.
Expert insights. Personalized for you.
263 
Let's personalize your content